ThromboGenics NV - Q3 2009 Business Update

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- The second Phase III study with microplasmin, TG-MV-007, which is recruiting 320 patients in Europe and the US, is progressing well and we expect complete enrolment within... [read full story]                    

powered by
Add Comment
There are also 4 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies